Our portfolio has expanded to include testing for folate receptor alpha expression – learn more below.
Fill out the form below to get in touch with your dedicated Myriad sales representative.
* Required field
Precise Oncology Solutions allows you to order both germline and somatic testing in one seamless experience.
Test for germline and somatic biomarkers in one order with Precise™ Oncology Solutions
Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including HRD† testing with one order.
† For patients with ovarian cancer.
* Precise Tumor, PD-L1, and FOLR1/FRα are powered by Intermountain Precision Genomics, a service of Intermountain Health. Precise Tumor and MyRisk are not approved by the FDA. FOLR1/FRα is an FDA-approved assay performed according to the intended use.
* Mirvetuximab is a product offered by ImmunoGen, Inc.
We’ve made it quick and simple to order all the necessary germline, somatic and HRD tests for each patient in one easy-to-use online portal experience.
Fill out a test request form in the Myriad Genetics provider portal.
Submit a blood or saliva sample for your patient’s germline test.
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for any somatic or HRD testing that is ordered.
Each test result is reported out as it becomes available in the portal, and you will be provided with an easy-to-interpret summary sheet for all tests ordered for each patient. Upon receipt of all reports, you will receive a high-level summary sheet*, signaling all results are in, and allowing you to minimize your time in report review.
*Summary sheet includes information from both FDA-approved and non-FDA-approved tests and will be reflective of the specific tests ordered for each patient
Join us each month to convene with clinical experts to provide state-of-the-art and evidence-based assessment of cases.
Topics can include:
This is not a CME event
Intended use – PMA intended use statement for BRACAnalysis CDx
BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.
Results of the test are used as an aid in identifying patients who are or may become eligible for treatment with the targeted therapies listed in Table 1 in accordance with the most recently approved therapeutic product labeling.
Table 1: companion diagnostic indications
This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108
LYNPARZA is a registered trademark of the AstraZeneca group of companies.